Comparison of the immune response induced in mice by five commercial vaccines based on recombinant HBsAg from different sources, implications on their therapeutic use

Biotecnologia Aplicada

Volumn 25, Issue 4, 2008, Pages 325-331

  Lobaina, Yadira ^a   García, Daymir ^a   Iglesias, Enrique ^a   Muzio, Verena ^a   Rodríguez, Diane ^b   Gorovaya, Laritza ^b   Pentón, Eduardo ^a   Guillén, Gerardo ^a   Aguilar, Julio C ^a  

^a Hepatitis B Department   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

HBsAg; HBV; Vaccine

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HEBERBIOVAC HB; HEPATITIS B SURFACE ANTIGEN; HEPAVAX GENE; IMMUNOGLOBULIN G; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; YEAST;

HEPATITIS B VIRUS; MUS;

EID: 76849092529     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hilleman, MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19: 1837-48.
2. Vanlandschoot P and Leroux-Roels G. Viral apoptotic mimicry: an immune evasion strategy developed by the hepatitis B virus? Trends Immunol 2003;24(3):144-7.
3. Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999;20:18(1-2):3-17.
4. Kumar GB, Ganapathi TR, Bapat VA. Production of hepatitis B surface antigen in recombinant plant systems: an update. Biotechnol Prog 2007;23:532-9.
5. Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux-Roels G. Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. J Gen Virol 2002;83:1281-89.
6. Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Stelter F, Peterson DL, et al. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipid moiety of the particles. J Gen Virol 2002;83: 2279-89.
7. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, et al. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34(6):917-21.
8. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999;180:1756.
9. Horiike N, Akbar F, Michitaka K, Joukou K, Yamamoto K, Kojima N, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-161.
10. Wettendorff M. Therapeutic vaccination. Virus Research 2002;82:133-40.
11. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25(51):8585-97.
12. Michel ML. Towards immunotherapy for chronic hepatitis B virus infections. Vaccine 2002;20(suppl 4):A83-8.
13. Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 2002;76:8609-20.
14. Chisari FV. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
15. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002;195:1089-101.
16. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, et al. Selective functional deficit in dendritic cell - T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004;11:217-24.
17. Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, et al. Hepatitis B virus induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 2003;109:487-95.
18. Li YG, Chen M, Zhang DZ. Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2003;11:206-8.
19. Bertoletti A, Ferrari C, Fiaccadori F. Role of the cell-mediated immune response in the pathogenesis of hepatitis B virus infection: possible immune-therapeutic strategies. Acta Biomed Ateneo Parmense 1996;67(3-4):87-93.
20. Webster G, Bertoletti A. Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 2001;38(6):467-73.
21. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-24.
22. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-71.
23. Código para el uso y cuidado de animales de laboratorio del CIGB. Actualización 2008.
24. Schirmbeck R, Wild J, Reimann J. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 1998;28:4149-61.
25. Estévez ZC, Betancourt AA, Muzio González V, Baile NF, Silva CV, Bernal FH, et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals 2007;35(2):115-22.
26. Baldy JL, de Lima GZ, Morimoto HK, Reiche EM, Matsuo T, de Mattos ED, et al. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination. Rev Inst Med Trop Sao Paulo 2004;46(2):103-7.
27. Joshi N, Kumar A, Sreenivas DV, Palan S, Nagarjuna Kumar YR. Safety and immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine. Indian J Gastroenterol 2000;19(2):71-3.
28. ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine 2003;21(23):3179-85.
29. Vanlandschoot P, Van Houtte F, Hoek F, Nieuwland R, Leroux-Roels G. Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity. J Med Virol 2003;70:513-519.
30. Van der Meeren P, Van Criekinge W, Vanderdeelen J, Baert L. Phospholipid composition of r-DNA hepatitis B surface antigens. Int J Pharm 1994;106:89-92.
31. de Roubin M-R, Cailas MD, Shen S-H, Groleau D. Influence of pH, nitrogen and phosphorus sources on the production of hepatitis B virus preS2 antigen by Hansenula polymorpha. Appl Microbial Biotechnol 1992;36:158-164.
32. Rattray JBM and Hambleton JE. The lipid components of Candida boidinii and Hansenula polymorpha grown on methanol. Can J Microbiol 1980;26:190-5.
33. Aguilar JC, Penton E, Tleugabulova D, Sewer M, Muzio V, Guillen G, et al. Method for obtaining antigenic aggregates and the use thereof in formulations. EP20010 998363, 24 Sep 2003.
34. Galban E, Bravo JR, Castañeda C, Toledo G, González A, Delgado MG. Field trial of the Cuban recombinant vaccine against hepatitis B (Heberbiovac HB). Study in newborn infants born to AgsHB+ mothers. Rev Cubana Med Trop 1992;44(2):149-57.
35. McCluskie MJ and Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161(9):4463-6.
36. Debin A, Kravtzoff R, Santiago JV, Cazales L, Sperandio S, Melber K, et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 2002;20(21-22):2752-63.
37. Bertoletti A and Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006;87(Pt 6):1439-49.
38. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101(17):6669-74.
39. Williamson, P and Schlegel, RA. Hide and seek: the secret identity of the phosphatidylserine receptor. J Biol 2004; 3(4):14.
40. Hoffmann PR, deCathelineau AM, Ogden CA, Leverrier Y, Bratton DL, Daleke DL, et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J Cell Biol 2001;155;4(12):649-59.
41. Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Stelter F, Peterson DL, et al. LPS-binding protein and CD14-dependent attachment of hepatitis B surface antigen to monocytes is determined by the phospholipids moiety of the particles. J Gen Virol 2002;83:2279-2289.
42. Kobayashi M, Asano T, Utsunomiya M, Itoh Y, Fujisawa Y, Nishimura O, et al. Recombinant hepatitis B carrying the pre-S2 region derived from yeast: purification and characterization. J Biotechnol 1988;8:1-22.
43. Tleugabulova D, Falcon V, Sewer M, Penton E. Aggregation of recombinant hepatitis B surface antigen in Picchia pastoris. J Chromatogr B 1998;716:209-219.
44. Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997;15(6-7):637-647.